Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients

British Journal of Dermatology

Volumn 135, Issue 4, 1996, Pages 538-544

  Boffa, M J ^a,d   Smith, A ^b   Chalmers, R J G ^a   Mitchell, D M ^a   Rowan, B ^b   Warnes, T W ^a   Shomaf, M ^c   Haboubi, N Y ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c WITHINGTON HOSPITAL   (United Kingdom)

^d HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMININ; METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIVER INJURY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS;

EID: 0029821519     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb03827.x     Document Type: Article

References (25)

1. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 1988; 19: 145-6.
2. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979; 76: 710-19.
3. Fessler JH, Fessler LI. Biosynthesis of collagen. Annu Rev Biochem 1978; 47: 129-62.
4. Fleischmajer R, Timpl R, Tuderman L et al. Ultrastructural identification of extension amino-propeptides of type I and III collagens in human skin. Proc Natl Sci Acad USA 1981; 78: 7360-4.
5. Frei A, Zimmerman A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity in degree of fibrosis in patients with chronic liver disease. Hepatology 1984; 4: 830-4.
6. Rojkind M. The blue glass and the predictive value of serum aminoterminal propeptide of type III procollagen as a marker of liver fibrosis. Hepatology 1984; 4: 977-8.
7. Eriksson S, Zettervall O. The N-terminal propeptide of collagen type III in serum as a prognostic indicator in primary biliary cirrhosis. J Hepatol 1986; 2: 370-8.
8. Colombo M, Annoni G, Donato MF et al. Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology 1985; 5: 475-9.
9. Hochweiss A, Fruchtman S, Hahn EG et al. Increased serum procollagen III aminoterminal peptide in myelofibrosis. Am J Hematol 1983; 15: 343-51.
10. Krieg T, Langer L, Hahn E et al. Type HI collagen aminopeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol 1986; 87: 788-91.
11. Zachariae H, Halkier-Sorensen L, Heickendorff L. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma. Acta Derm Venereol (Stockh) 1989; 69: 66-70.
12. Blomqvist C, Elomaa I, Virkkunen P et al. Response evaluation of bony metastases in mammary carcinoma. The value of radiology, scintigraphy and biochemical markers of bone metabolism. Cancer 1987; 60: 2907-12.
13. Charrie AM, Fleury-Goyon MC, Dutey P, Tourniaire J. Procollagen-III peptide and hyperthyroidism. Lancet 1986; ii: 1221.
14. Schuppan D. Structure of the extracellular matrix in normal and librotic liver: collagens and glycoproteins. Semin Liver Dis 1990; 10: 1-10.
15. Babbs C, Haboubi NY, Mellor JM et al. Endothelial cell transformation in primary biliary cirrhosis. A morphological and biochemical study. Hepatology 1990; 11: 723-9.
16. Mitchell DM, Smith A, Rowan B et al. Serum PIIINP, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving MTX. Br J Dermatol 1990; 122: 1-7.
17. Risteli J, Sogaard H, Oikarinen A et al. Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis. Br J Dermatol 1998; 119: 321-5.
18. Zachariae H, Muhammad Aslam H, Bjerring P et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25: 50-3.
19. Mitchell DM, Johnson RJ, Testa HJ et al. Ultrasound and radionuclide scans - poor indicators of liver damage in psoriatic patients treated with methotrexate. Clin Exp Dermatol 1987; 12: 243-5.
20. Boffa MJ, Chalmers RJG, Haboubi NY et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133: 774-8.
21. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1982; 6: 145-55.
22. Oogarah PK, Rowland PL, Mitchell DM et al. Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes. Br J Dermatol 1995; 133: 512-18.
23. Piccinino F, Sagnelli, Pasquale G et al. Complications following percutaneous liver biopsy - A multicentre, retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.
24. Creswell SN, Burrows D. Liver biopsies in psoriatics. Complications and evaluation. Int J Dermatol 1980; 19: 217-19.
25. Cork M. Kconomic considerations in the treatment of psoriasis. Dermatology Pract 1993; Jan/Feb: 16-20.